You are here

KINEMED, INC.

Company Information
Address
KINEMED, INC. 5980 HORTON ST, STE 470
EMERYVILLE, CA 94608-
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. IGF::OT::IGF Kinetic Biomarkers of Myocardial Fibrogenesis- SBIR Topic 072- Pha

    Amount: $225,087.00

    Myocardial fibrosis is a crucial marker of adverse cardiac remodeling. Research suggests a strong correlationbetween the extent of myocardial fibrosis and adverse myocardial remodeling that occurs aft ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  2. The application of human collagen kinetic biomarkers to anti-fibrotic drug develo

    Amount: $1,223,900.00

    DESCRIPTION (provided by applicant): Fibrosis can be defined as an uncontrolled wound healing response that results in organ dysfunction. Fibroproliferation leads to the over production and increased ...

    SBIRPhase II2009Department of Health and Human Services National Institutes of Health
  3. An in Vivo Neurogenesis Assay to Discover Antidepressants and Cognitive Enhancers

    Amount: $249,998.00

    DESCRIPTION (provided by applicant): Hippocampal neurogenesis represents a promising target for discovery of novel therapeutic agents for disorders of mood and cognition. All known antidepressants sti ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  4. A Novel Biomarker for Myelin Synthesis

    Amount: $124,521.00

    DESCRIPTION (PROVIDED BY APPLICANT): Development of new treatment strategies for demyelinating disorders such as multiple sclerosis (MS), as well as assessment of disease status and efficacy of exist ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  5. Kinetic Biomarker for CLL Prognosis

    Amount: $4,464,850.00

    DESCRIPTION (provided by applicant) PHASE I The need for reliable biomarkers in cancer is clear, for areas including prognosis, stratification, therapeutic monitoring and drug discovery and approva ...

    SBIRPhase II2004Department of Health and Human Services National Institutes of Health
  6. In Vivo Kinetic Biomarkers of Hepatic Toxicity

    Amount: $494,086.00

    DESCRIPTION (provided by applicant): A flood of drug candidates increases the need for novel assays to measure liver toxicity. We have developed methods for quantifying multiple metabolic fluxes i ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  7. Kinetic Biomarker for CLL Prognosis

    Amount: $153,224.00

    DESCRIPTION (provided by applicant) PHASE I The need for reliable biomarkers in cancer is clear, for areas including prognosis, stratification, therapeutic monitoring and drug discovery and approva ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government